Annual CFF
$6.27 M
+$6.66 M+1712.32%
December 31, 2023
Summary
- As of February 7, 2025, PCSA annual cash flow from financing activities is $6.27 million, with the most recent change of +$6.66 million (+1712.32%) on December 31, 2023.
- During the last 3 years, PCSA annual CFF has fallen by -$11.60 million (-64.92%).
- PCSA annual CFF is now -64.92% below its all-time high of $17.87 million, reached on December 31, 2020.
Performance
PCSA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$926.20 K
+$929.60 K+27341.18%
September 30, 2024
Summary
- As of February 7, 2025, PCSA quarterly cash flow from financing activities is $926.20 thousand, with the most recent change of +$929.60 thousand (+27341.18%) on September 30, 2024.
- Over the past year, PCSA quarterly CFF has dropped by -$5.34 million (-85.21%).
- PCSA quarterly CFF is now -94.67% below its all-time high of $17.37 million, reached on December 31, 2020.
Performance
PCSA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$7.16 M
+$978.90 K+15.85%
September 30, 2024
Summary
- As of February 7, 2025, PCSA TTM cash flow from financing activities is $7.16 million, with the most recent change of +$978.90 thousand (+15.85%) on September 30, 2024.
- Over the past year, PCSA TTM CFF has increased by +$975.50 thousand (+15.79%).
- PCSA TTM CFF is now -74.21% below its all-time high of $27.75 million, reached on March 31, 2021.
Performance
PCSA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
PCSA Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1712.3% | -85.2% | +15.8% |
| 3 y3 years | -64.9% | +1828.0% | +1940.3% |
| 5 y5 years | +138.9% | +1828.0% | +1940.3% |
PCSA Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -36.0% | +1712.3% | -85.4% | +408.7% | -27.0% | +1940.3% |
| 5 y | 5-year | -64.9% | +1712.3% | -94.7% | +408.7% | -74.2% | +1940.3% |
| alltime | all time | -64.9% | +1712.3% | -94.7% | +367.3% | -74.2% | +1940.3% |
Processa Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $926.20 K(<-9900.0%) | $7.16 M(+15.8%) |
| Jun 2024 | - | -$3400.00(-100.1%) | $6.18 M(-0.1%) |
| Mar 2024 | - | $6.26 M(<-9900.0%) | $6.18 M(-1.4%) |
| Dec 2023 | $6.27 M(-1712.3%) | -$30.60 K(-41.9%) | $6.27 M(+0.4%) |
| Sep 2023 | - | -$52.70 K(<-9900.0%) | $6.25 M(-0.3%) |
| Jun 2023 | - | $0.00(-100.0%) | $6.26 M(0.0%) |
| Mar 2023 | - | $6.35 M(<-9900.0%) | $6.26 M(-1710.9%) |
| Dec 2022 | -$388.80 K(-104.0%) | -$53.60 K(+52.3%) | -$388.80 K(+90.8%) |
| Sep 2022 | - | -$35.20 K(<-9900.0%) | -$203.80 K(-42.4%) |
| Jun 2022 | - | $0.00(-100.0%) | -$353.80 K(-6.1%) |
| Mar 2022 | - | -$300.00 K(-328.3%) | -$376.90 K(-103.8%) |
| Dec 2021 | $9.80 M(-45.2%) | $131.40 K(-171.0%) | $9.80 M(-63.8%) |
| Sep 2021 | - | -$185.20 K(+701.7%) | $27.03 M(-0.1%) |
| Jun 2021 | - | -$23.10 K(-100.2%) | $27.06 M(-2.5%) |
| Mar 2021 | - | $9.88 M(-43.1%) | $27.75 M(+55.3%) |
| Dec 2020 | $17.87 M(+950.6%) | $17.37 M(<-9900.0%) | $17.87 M(+1271.8%) |
| Sep 2020 | - | -$156.40 K(-123.7%) | $1.30 M(-33.6%) |
| Jun 2020 | - | $661.00 K(<-9900.0%) | $1.96 M(+24.0%) |
| Mar 2020 | - | -$2800.00(-100.3%) | $1.58 M(-6.9%) |
| Dec 2019 | $1.70 M(-35.2%) | $800.70 K(+58.8%) | $1.70 M(+149.8%) |
| Sep 2019 | - | $504.10 K(+79.5%) | $680.70 K(+138.3%) |
| Jun 2019 | - | $280.90 K(+144.3%) | $285.60 K(-89.6%) |
| Mar 2019 | - | $115.00 K(-152.4%) | $2.74 M(+4.4%) |
| Dec 2018 | $2.62 M | -$219.30 K(-301.2%) | $2.62 M(-46.9%) |
| Sep 2018 | - | $109.00 K(-96.0%) | $4.94 M(-2.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | $2.73 M(+30.3%) | $5.08 M(+109.6%) |
| Dec 2017 | $2.43 M(>+9900.0%) | $2.10 M(+732.6%) | $2.43 M(+641.7%) |
| Sep 2017 | - | $252.00 K(+236.0%) | $327.00 K(+336.0%) |
| Jun 2017 | - | $75.00 K(>+9900.0%) | $75.00 K(>+9900.0%) |
| Mar 2017 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 2016 | $15.00 K(-98.2%) | $0.00(0.0%) | $15.00 K(0.0%) |
| Sep 2016 | - | $0.00(0.0%) | $15.00 K(-75.8%) |
| Jun 2016 | - | $0.00(-100.0%) | $62.10 K(-80.1%) |
| Mar 2016 | - | $15.00 K(>+9900.0%) | $312.00 K(-62.0%) |
| Dec 2015 | $821.10 K(-68.1%) | $0.00(-100.0%) | $821.00 K(-35.3%) |
| Sep 2015 | - | $47.10 K(-81.2%) | $1.27 M(-29.0%) |
| Jun 2015 | - | $249.90 K(-52.3%) | $1.79 M(-18.9%) |
| Mar 2015 | - | $524.00 K(+17.1%) | $2.21 M(-14.4%) |
| Dec 2014 | $2.57 M(+48.7%) | $447.50 K(-20.9%) | $2.57 M(+44.6%) |
| Sep 2014 | - | $566.00 K(-15.2%) | $1.78 M(-23.1%) |
| Jun 2014 | - | $667.70 K(-25.3%) | $2.32 M(-12.0%) |
| Mar 2014 | - | $893.50 K(-357.9%) | $2.63 M(+52.0%) |
| Dec 2013 | $1.73 M(+282.0%) | -$346.50 K(-131.4%) | $1.73 M(-26.9%) |
| Sep 2013 | - | $1.10 M(+12.1%) | $2.37 M(+65.7%) |
| Jun 2013 | - | $983.30 K(<-9900.0%) | $1.43 M(+220.1%) |
| Mar 2013 | - | -$6700.00(-102.3%) | $446.70 K(-1.5%) |
| Dec 2012 | $453.40 K | $291.40 K(+79.9%) | $453.40 K(+179.9%) |
| Sep 2012 | - | $162.00 K(>+9900.0%) | $162.00 K(>+9900.0%) |
| Jun 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2012 | - | $0.00 | $0.00 |
FAQ
- What is Processa Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Processa Pharmaceuticals?
- What is Processa Pharmaceuticals annual CFF year-on-year change?
- What is Processa Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Processa Pharmaceuticals?
- What is Processa Pharmaceuticals quarterly CFF year-on-year change?
- What is Processa Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Processa Pharmaceuticals?
- What is Processa Pharmaceuticals TTM CFF year-on-year change?
What is Processa Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of PCSA is $6.27 M
What is the all time high annual CFF for Processa Pharmaceuticals?
Processa Pharmaceuticals all-time high annual cash flow from financing activities is $17.87 M
What is Processa Pharmaceuticals annual CFF year-on-year change?
Over the past year, PCSA annual cash flow from financing activities has changed by +$6.66 M (+1712.32%)
What is Processa Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of PCSA is $926.20 K
What is the all time high quarterly CFF for Processa Pharmaceuticals?
Processa Pharmaceuticals all-time high quarterly cash flow from financing activities is $17.37 M
What is Processa Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, PCSA quarterly cash flow from financing activities has changed by -$5.34 M (-85.21%)
What is Processa Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of PCSA is $7.16 M
What is the all time high TTM CFF for Processa Pharmaceuticals?
Processa Pharmaceuticals all-time high TTM cash flow from financing activities is $27.75 M
What is Processa Pharmaceuticals TTM CFF year-on-year change?
Over the past year, PCSA TTM cash flow from financing activities has changed by +$975.50 K (+15.79%)